Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 76NIH 13NETWORK 5INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Glioblastoma 40Carcinoma, Non-Small-Cell Lung 22Head and Neck Neoplasms 20Brain Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Glioma 11Lung Neoplasms 8Carcinoma, Squamous Cell 8Breast Neoplasms 8Astrocytoma 8Rectal Neoplasms 7Neoplasms 7Prostatic Neoplasms 6Mucositis 5Esophageal Neoplasms 5Carcinoma 4Neoplasm Metastasis 3Esophageal Squamous Cell Carcinoma 3Colorectal Neoplasms 3Xerostomia 2Stomatitis 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Neoplasms, Squamous Cell 2Lymphoma 2Leukemia 2Laryngeal Diseases 2Gliosarcoma 2Adenocarcinoma Of Esophagus 2Adenocarcinoma 2

Interventions

Gemcitabine 205130-nm albumin-bound paclitaxel 84Albumin-Bound Paclitaxel 57pembrolizumab 43Fluorouracil 41Leucovorin 34Oxaliplatin 33Capecitabine 25Nivolumab 22Irinotecan 19Bevacizumab 17Paclitaxel 16Cyclophosphamide 15Cetuximab 15Taxes 13Erlotinib Hydrochloride 13Drug Therapy 13Carboplatin 12irinotecan sucrosofate 11Injections 10Cisplatin 9fludarabine 8ALT-803 8spartalizumab 7olaparib 7avelumab 7Pemetrexed 7Docetaxel 7ruxolitinib 6TH 302 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Pancreatic Neoplasms × Radiotherapy × Clear all
NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DEKA Biosciences

Phase 1 Active not recruiting
39 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT00191568 2007-10-19

Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer

Eli Lilly and Company

Phase 2 Completed
45 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡